Renaissance Capital logo

Frazier Life Sciences Acquisition II

Filed Terms, Nasdaq: FLSC

Second blank check company formed by Frazier targeting biotech.

Industry: SPAC

Frazier Life Sciences Acquisition Corp. II is a newly organized blank check company. While we may pursue an initial business combination opportunity in any business, industry, sector or geographical location, we intend to capitalize on the experience and ability of our management team to identify promising opportunities in the biotechnology sector, with the goal of financing a company that can develop important new therapies for patients while creating value for shareholders. Our sponsor is Frazier Life Sciences Holdings II LLC, an affiliate of Frazier Life Sciences Management, L.P. (“FLS”). FLS originated as part of Frazier Healthcare Partners, which was founded in 1991 and combined healthcare growth buyout and life sciences strategies as one of the first healthcare-dedicated investment firms. The life sciences strategy was separated into dedicated funds and decision-making in 2005 and became a separate management company and legal entity in 2022. Today, FLS invests across venture capital and public equity strategies, with dedicated funds for each.
IPO Data
IPO File Date 09/24/2026
Offer Price n/a
Price Range $10.00 - $10.00
Offer Shares (mm) 7.5
Deal Size ($mm) $75
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Underwriter Name Jefferies
Company Data
Headquarters Palo Alto, CA, United States
Founded 2026
Employees at IPO 4
Website frazierls.com

Frazier Life Sciences Acquisition II (FLSC) Performance